Compare BUR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUR | NVCR |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | Guernsey | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2017 | 2015 |
| Metric | BUR | NVCR |
|---|---|---|
| Price | $4.99 | $12.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $13.58 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 6.1M | 1.0M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.28 | N/A |
| Revenue | $413,360,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $104.62 | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $3.59 | $9.82 |
| 52 Week High | $14.61 | $20.05 |
| Indicator | BUR | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 63.26 |
| Support Level | $3.59 | $12.66 |
| Resistance Level | $9.59 | $13.34 |
| Average True Range (ATR) | 0.30 | 0.54 |
| MACD | 0.13 | 0.28 |
| Stochastic Oscillator | 97.31 | 92.75 |
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.